Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

ConclusionHS016 resembled adalimumab in efficacy and safety over the 24-week treatment period.Trial registration numberChiCTR1900022520.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research